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Abstract
Background: Since the first articles published for over 10 years ago, endobronchial ultrasound (EBUS) has gained a
strong scientific backing and has been incorporated into routine medical practice in pulmonology and thoracic
surgery centers. How is EBUS performing outside the scientific environment, as a diagnostic and mediastinal
staging tool in a subset of patients that undergo thoracic surgery, is an interesting question.
Methods: This study evaluated consecutive patients who, during the period from January 2010 to August 2012,
were submitted to EBUS and later to thoracic surgery. The samples obtained by endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA) were compared to surgical samples. The primary
endpoint was the proportion of patients with a final diagnosis of non-small cell lung cancer (NSCLC) by
EBUS-TBNA correctly subtyped. The secondary endpoint was the negative predictive value (NPV) of EBUS-TBNA
for mediastinal staging of lung cancer.
Results: Two hundred eighty seven patients were studied. Considering 84 patients with a final diagnosis of
NSCLC by EBUS-TBNA, 79 % (CI 95 % 70.1–87.3) were correctly subclassified. The NPV of EBUS-TBNA for
mediastinal staging was 89 % (IC 95 % 84.9–92.7). From a total of 21 false negative cases of mediastinal
staging, 16 (76 %) did not undergo positron emission tomography-computed tomography (PET-CT) before the
EBUS and in 15 (71 %) the affected lymph node chain was not punctured by EBUS-TBNA. Ten (47 %) patients
had only lymph node metastases not directly accessible by the EBUS.
Conclusions: Performed in hospital routine and in patients submitted to thoracic surgery, EBUS-TBNA proved to be a
good tool for proper pathological diagnosis of lung cancer. The negative predictive value of 89 % for mediastinal
staging of lung cancer is comparable to that reported in previous studies, but the relatively high number of 21 false
negative cases points to the need for standardization of routine strategies before, during and after EBUS.
Background
Lung cancer is the malignant tumor with the highest mor-
tality rate among men and women worldwide, with more
than 1,4 million deaths a year [1]. The emergence of endo-
bronchial ultrasound-guided transbronchial needle aspir-
ation (EBUS-TBNA), a minimally invasive technique able
to provide valuable information for a primary tumor diag-
nosis and mediastinal staging, significantly changed the ap-
proach to lung cancer [2, 3]. Since the first articles
published for over 10 years ago [4], endobronchial ultra-
sound (EBUS) has gained strong scientific backing [5–7]
and has been incorporated into routine medical prac-
tice of pulmonology and thoracic surgery centers.
Guidelines of respiratory societies reinforce the import-
ance of ultrasound-guided needle techniques in the pri-
mary diagnosis and mediastinal staging of lung cancer
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[8–11]. The success of the technique and the spread of
its use around the world make it important to revaluate
its performance in “real life”, outside the scientific en-
vironment, especially in patients undergoing thoracic
surgery, in which the sharpest staging tools are
required.
The aim of our study is to determine EBUS performance
in patients undergoing thoracic surgery in hospital rou-
tine. Using surgical pathology as the gold standard, we cal-
culated the proportion of patients with a final diagnosis of
non-small cell lung cancer (NSCLC) by EBUS-TBNA cor-
rectly subtyped and the performance of EBUS-TBNA for
the mediastinal staging of lung cancer.
Methods
Study design
The present work is a single-center, retrospective, obser-
vational study. All patients who underwent EBUS and
thoracic surgery during the period from January 2010 to
August 2012 were selected.
Procedures
The examinations and surgeries took place in the Lungen-
klinik Hemer, a traditional center for respiratory diseases in
Germany. EBUS procedures were performed on hospital-
ized patients, under general anesthesia. The examination
could be accompanied by the presence of a pathologist in
the procedure room for rapid on-site evaluation (ROSE) or
not. EBUS-TBNA samples were collected using a 22-gauge
needle. At least 2 aspirates were obtained from each target
lesion. When a pathologist was present, 2 pairs of smears
were prepared for ROSE and cytologic examinations. The
resulting material (tissue cores, shreds of tissue, cellular
components, fluids) was processed using a cell-block tech-
nique. If there was no pathologist in the room, all the sam-
ples were processed as cell-blocks. Indications for a surgical
exploration or resection due to suspicion or confirmation
of lung cancer were discussed and had to be approved by a
local interdisciplinary clinical session with the mandatory
participation of pulmonologists, oncologists, chest sur-
geons, radiologists and radiotherapists. EBUS-TBNA
and surgical samples were analyzed by two different
pathology services.
Data collection
Data collection and statistical analysis were conducted at
the Federal University of Rio de Janeiro, Brazil. Through
the computer program Teamviewer ® (TeamViewer
GmbH, Germany) the authors had remote access to a
database provided by the Lungenklinik Hemer to access
patient data from local electronic medical records.
Inclusion criteria
Patients who underwent EBUS for any indication in the
Lungenklinik Hemer from January 2010 to August 2012
and were subsequently subjected to surgical procedures.
Exclusion criteria
Patients with no lymph node sampling by EBUS-TBNA
during an EBUS procedure or patients who did not have
histopathologic sampling of mediastinal lymph nodes
during surgery.
Study population
Patients were identified in the electronic system of the
Lungenklinik Hemer by crossing the specific code repre-
senting the EBUS with codes representing thoracic surgical
procedures such as thoracotomy, thoracoscopy or medias-
tinoscopy. Patients whose electronic records showed both
codes in the same hospital stay were selected. Four hun-
dred thirty-nine patients underwent both an EBUS and
thoracic surgery between January 2010 and August 2012
in the Lungenklinik Hemer. One hundred fifty-two cases
were excluded for not having mediastinal lymph node
sampling from both EBUS and surgery. The remaining
287 patients were studied (Fig. 1).
Endpoints
The primary endpoint was the proportion of patients with
a final diagnosis of NSCLC by EBUS-TBNA correctly sub-
typed as compared to the surgical samples. The secondary
endpoint was the negative predictive value (NPV) of EBUS-
TBNA for mediastinal staging of lung cancer, according to
the 7th edition of the lung cancer staging system of the
American Joint Committee on Cancer [12].
439 
• EBUS and thoracic 
surgery from January 
2010 to August 2012
152
• Patients excluded: no 
lymph node sampling by 
EBUS-TBNA / no 
histopathologic sampling of 
mediastinal lymph nodes 
during surgery 
287
•Total of patients 
studied
Fig. 1 Flow chart showing selection, exclusion and total of patients studied. EBUS: endobronchial ultrasound. EBUS-TBNA: endobronchial
ultrasound-guided transbronchial needle aspiration
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Statistical analysis
Patient demographics and disease characteristics were
summarized using descriptive statistics. For the primary
endpoint, the final result of the pathology after surgical
resection was used as the gold standard for comparison
to EBUS-TBNA samples. This result takes into account
the tumor samples present in the lung parenchyma and/
or mediastinum. There was no pairing of samples per
lymph node site. For the secondary endpoint, the EBUS-
TBNA samples were compared only to mediastinal sur-
gical samples (obtained by mediastinoscopy and/or sur-
gical mediastinal lymphadenectomy). The proportion of
NSCLC correctly subclassified, the NPV for mediastinal
staging and their 95 % confidence intervals (CI) were
calculated using standard definitions. All statistical ana-
lyses were performed using SPSS® (IBM SPSS Statistics
Version 20, United States of America).
Results
The demographic data, tumor characteristics and details
of the procedures performed are summarized in Table 1.
The samples obtained by EBUS-TBNA showed no
pathological findings in 188 patients (65.5 %) (represen-
tative lymph node samples without disease). NSCLC was
detected in 84 patients (29.2 %), other malignant dis-
eases in 8 (2.7 %) and benign pathological findings in 7
(2 %) patients (Table 2). Considering the 188 patients
without pathological findings in samples of EBUS-
TBNA, 156 had a final diagnosis of NSCLC after sur-
gery. Of these, the final surgical mediastinal staging was
N0 in 104 patients, N1 in 39 patients and N2 in 13 pa-
tients (Fig. 2). In 99 patients it was possible to compare
the pathological findings of the EBUS-TBNA samples
with the surgical findings. Taking into account NSCLC
subtyping analysis, EBUS-TBNA was correct in 67 cases
and incorrect or incomplete in 17 cases (Fig. 3). Four pa-
tients were diagnosed as NSCLC not otherwise specified
(NSCLC-NOS) by EBUS and were determined to be
squamous cell carcinoma (3 patients) or adenocarcin-
oma (1 patient) after the surgical resection; 1 was classi-
fied as pulmonary adenocarcinoma and determined to
be adenosquamous carcinoma from the surgical sample;
7 were diagnosed as squamous cell carcinoma or adeno-
carcinoma and the surgical pathology showed large cell
carcinoma; 2 cases were subtyped as squamous cell car-
cinoma and the surgical sample determined a diagnosis
of adenocarcinoma; 1 case of adenocarcinoma by EBUS-
TBNA was determined to be squamous cell carcinoma
by the surgical sample; 1 case classified as adenocarcin-
oma by EBUS-TBNA and was determined as sarcoma-
tous carcinoma by the surgical sample; and 1 single case
of false malignancy of adenocarcinoma with the EBUS-
TBNA samples, and surgical resection confirmed a diag-
nosis of hamartoma. Considering this subclassification,




Male gender, N (%) 204 (71.1)
Smoking History, N (%) 126 (43.9)a
COPD, N (%) 81 (28.2)
Cardiovascular Disease, N (%) 148 (51.6)
Cancer History, N (%) 42 (14.6)b
Lung Cancer History, N (%) 11 (3.8)
Instersticial Lung Disease, N (%) 4 (1.4)





















Total Lymph Nodes punctured, N (mean) 849 (2.95)













EBUS with ROSE, N (%) 130 (45.3)
Additional Biopsy, N (%)

























NSCLC after surgical exploration, N (%) 238 (82.9 %)
















COPD chronic obstructive pulmonary disease, Cardiovascular Disease coronary
arterial disease, arterial hypertension, ischemic or hemorrhagic brain disease,
peripheral vascular disease, atrial fibrillation, aortic aneurysm, EBUS endobronchial
ultrasound, ROSE rapid on-set evaluation, NSCLC non-small cell lung cancer
asmoking history could be assessed only when evidenced in the hospital
discharge letter
bhistory of any cancer other than lung cancer
cconsidering 238 patients with NSCLC and 4 patients with Carcinoid Tumor
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the proportion of patients with a final diagnosis of
NSCLC by EBUS-TBNA in whom NSCLC subtyping
was correct was 79 % (IC 95 % 70.1-87.3).
The EBUS-TBNA performance for the mediastinal sta-
ging of lung cancer was calculated by taking into account
all 238 patients with NSCLC who had mediastinal lymph
node sampling by both EBUS and surgery (Table 3). EBUS
staging was correct in 213 cases and incorrect in 25. There
were 180 true negative, 33 true positive, 21 false negative
and 4 false positive findings. Those findings allowed us to
calculate the NPV of 89 % (CI 95 % 84.5-93), the positive
predictive value (PPV) of 89 % (72.5–95.7) the sensibility of
61 % (CI 95 % 47.8-72.9) and the specificity of 97 % (CI
95 % 94.5-99.1). From the 21 false negative cases, 16 (76 %)
did not undergo positron emission tomography-computed
tomography (PET-CT) or it was performed after the EBUS.
In 15 (71 %) patients the affected lymph node chain was
not punctured by EBUS-TBNA. Ten (47 %) patients had
only lymph node metastases not directly accessible by the
EBUS (lymph node chains 5,6,8 and 9). In 11 (52 %) pa-
tients the tumor was located in the left superior lobe. The
more often affected lymph node chain was station 5, with 7
false negative cases.
Considering the 4 false positive cases, 2 were surgically
classified as N1 and 2 were classified as N0 (all confirmed
surgically as NSCLC). In just one of the cases there was a
disagreement of the pathological findings of EBUS-TBNA
and surgery (EBUS-TBNA suggested adenocarcinoma and
surgery confirmed large cell carcinoma). All the 4 cases
were submitted to surgical lobectomy and lymph node
dissection.
Twenty patients had a mediastinoscopy after the EBUS
(4 as the main surgical procedure and 16 as part of the
mediastinal staging before surgery). There were 15 true
negative, 1 true positive, 4 false negative and no false
positive findings comparing mediastinoscopy to final
surgical mediastinal staging. Mediastinoscopy did not
contribute to a better mediastinal staging than the EBUS
in any of the patients. All the 15 true negative cases were
also negative by the EBUS. The true positive case was
also positive by the EBUS, and one of the 4 false negative
mediastinoscopies cases was positive by the EBUS.
Discussion
Our study evaluated the EBUS-TBNA performance in a
key subset of patients with lung cancer: those undergoing
thoracic surgery. Despite not representing the majority of
patients diagnosed with lung cancer, this is the subgroup
in which we need to have the sharpest diagnostic and sta-
ging tools to ensure an accurate referral to surgery and ex-
pectation of cure. To our knowledge, this is the work with
the highest number of patients submitted to surgery who
had their EBUS-TBNA results directly compared with the
surgical sampling. The use of EBUS was evaluated in a
hospital routine, without adherence to study protocols in-
fluencing the exam.
The primary endpoint of the study was the proportion
of patients with a final diagnosis of NSCLC by EBUS-
TBNA correctly subtyped. Our results show that NSCLC
was correctly subclassified in 79 % of cases. One of the
limitations of existing evidence on EBUS diagnostic per-
formance is that many studies included results of the
index test and clinical follow-up in a reference standard
test and did not account for the surgical sample being
the only possible gold standard. This may have overesti-
mated the result of some studies [13]. Esterbrook et al.
showed that EBUS-TBNA samples when made into cell-
blocks and subjected to a panel of immunohistochemical
Table 2 EBUS-TBNA pathological findings
Absence of pathological findings, N (%)a 188 (65.5)
Squamous Cell Carcinoma, N (%) 40 (13.9)
Adenocarcinoma, N (%) 38 (13.2)
Large Cell carcinoma, N (%) 1 (0.3)
Adenosquamous Carcinoma, N (%) 1 (0.3)
NSCLC-NOS, N (%) 4 (1.3)
Clear Cell Carcinoma, N (%) 1 (0.3)
Undifferentiated Carcinoma, N (%) 2 (0.7)
Neuroendocrine Tumor, N (%) 1 (0.3)
Thymoma, N (%) 1 (0.3)
Lymphoproliferative Process, N (%) 2 (0.7)
Sarcomatous Process, N (%) 1 (0.3)
Anthracosis and Silica, N (%) 1 (0.3)
Granulomatous Process, N (%) 4 (1.4)
Inflammatory Process, N (%) 2 (0.7)
Total, N (%) 287 (100 %)
NSCLC-NOS non-small cell lung cancer not otherwise specified
arepresentative lymph node samples without disease
Table 3 Mediastinal Lymph Node Staging: EBUS-TBNA X Surgery
EBUS-TBNA N stage Final N stage Number of cases
Correctly staged




0 or 1 2 20
2 0 or 1 4
2 3 1
EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration
Total of patientes with NSCLC: 238
True positive: 33 / True negative: 180 / False positive: 4 / False negative: 21
Sensibility: 61% (CI 95% 47.8-72.9) / Specificity 97% (CI 95% 94.5-99.1) /
Positive predictive value 89% (CI 95% 75.2-95.7) / Negative predictive value: 89
(CI 95% 84.5-93)
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Fig. 2 Flow chart showing the 188 cases with samples without pathological findings by EBUS-TBNA and the final pathological results after surgery. *
EBUS-TBNA representative samples without pathological findings. ** surgical samples with malign pathological findings others than NSCLC. *** surgical
samples with benign pathological findings. **** surgical samples without pathological findings
Fig. 3 Flow chart showing pathological findings of the EBUS-TBNA samples; NSCLC subtyping by EBUS-TBNA and corrections after surgical resection.
EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration. NSCLC: non-small cell lung cancer. NSCLC NOS: non-small cell lung
cancer not otherwise specified. * EBUS-TBNA samples with positive pathological findings. ** EBUS-TBNA samples with malign pathological findings
others than NSCLC. ***EBUS-TBNA samples with benign pathological findings
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stains returned adequate tissue for NSCLC subtyping in
79 %, with a NSCLC-NOS reate of 21 % [14]. In a large,
multicenter study, Navani et al. demonstrated that sam-
ples from EBUS-TBNA provide sufficient information
for subtyping NSCLC in 77 % of the cases [15].
We chose the NPV of EBUS-TBNA for the mediastinal
staging of lung cancer as the secondary endpoint of our
study because we consider it to be the most clinically rele-
vant measure in the subset of patients who undergo thor-
acic surgery. From a total of 238 patients with NSCLC
surgically evaluated, 53 had mediastinal metastatic in-
volvement ipsilateral to the target tumor lesion (N2 dis-
ease) and 2 had contralateral mediastinal involvement (N3
disease), representing a prevalence of mediastinal nodal
involvement of 23 %. The results of our study showed an
NPV of 89 %. Probably some of the most important publi-
cations of EBUS and mediastinal lymph node staging in
patients with potentially resectable NSCLC are the ASTER
trial [16], published in 2010, and the work of Yasufuku et
al. [17], published in 2011. The ASTER trial found an
NPV for endosonography staging alone without additional
surgical staging of 85 % (prevalence of N2/N3 54 %). Yasu-
fuku showed an NPV of 91 % for EBUS-TBNA (preva-
lence of N2/N3 disease 35 %).
The sensitivity of 61 % in our work was lower than ex-
pected and previously reported. This fact is due to the
relatively high number of 21 false negative cases. In
reviewing such cases we realize that 16 (76 %) did not
undergo PET-CT or it was performed after EBUS and in
15 (71 %) the affected lymph node chain was not punc-
tured by EBUS-TBNA. In the ASTER trial [16] all patients
underwent PET-CT before EBUS. In the discussion of the
Lung-BOOST trial [18], the authors suggest that a PET-
CT may not be needed before EBUS-TBNA. In that trial
EBUS-TBNA was performed using a systematic aspiration
of all visible lymph node stations. Unfortunately, in our
study, we are unable to determine if most of the proce-
dures adopted a systematic or selective approach.
In 11 (52 %) patients from the false negative cases, the
tumor was located in the left superior lobe and 10
(47 %) had only lymph node metastases not directly ac-
cessible by EBUS (lymph node stations 5, 6, 8 and 9).
Endoscopic ultrasound (EUS), using the same scope as
EBUS, was done in only 6 of our 287 cases. None of the
false negative cases underwent also EUS in the same
procedure as EBUS. The current consensus is that for a
more complete needle-guided ultrasound evaluation of
the mediastinum we should associate EBUS and EUS
whenever necessary [19, 20]. Perhaps with the more fre-
quent use of EUS in routine practice, some false negative
results could have been avoided. However, even though
recently showed to be feasible and safe [21], it would still
be difficult to access the lymph nodes in chains 5 (the
most often affected) and 6. This points to the need for
more cautious strategies in patients susceptible to me-
tastases in these chains, such as patients with tumors in
the left superior lobe.
The 4 false positive cases represent patients with NSCLC.
Unfortunately we do not have follow-up data, so is difficult
to affirm that these are really false positive cases or maybe
incorrectly surgically staged patients
The small number of 20 mediastinoscopies already re-
flects the lower use of this technique in our hospital rou-
tine. All mediastinoscopies were performed after EBUS
to clarify questionable situations before the final surgical
decision. Mediastinoscopy did not contribute to better
mediastinal staging than EBUS-TBNA in any of those
patients. These findings do not reflect the results of the
ASTER trial [16] or corroborate the current recommen-
dations of the main guidelines of American and Euro-
pean respiratory societies.
Limitations
Some limitations apply to this study. First, it is a single-
center study. We recognize that our results cannot be eas-
ily generalized. EBUS was performed in hospitalized pa-
tients under general anesthesia. Although this is a standard
practice in our service, many procedures, probably the ma-
jority, performed in other bronchoscopy services around
the world are performed in conscious or moderate sed-
ation. Even tough the World Association for Bronchology
and Interventional Pneumology (WABIP) guidelines [22]
state that there is not enough evidence to recommend for
or against any type of anesthesia, ideally, we should also
have data in patients undergoing the procedure under con-
scious or moderate sedation. Second; two distinct path-
ology services have analyzed the samples obtained by
EBUS-TBNA and surgery, which may have prevented re-
sults of one of the tests influencing the analysis of the other
test. But it is difficult to clarify if the differences in patho-
logical classification are due to the quality of the samples
or a distinct interpretation by the pathologists. Third, at
least 2 aspirates were routinely obtained from each target
lesion per EBUS. Lee and colleagues [23] showed that, in
the absence of ROSE, at least 3 aspirates should be ob-
tained from each target lesion in order to provide optimal
results from the test. Unfortunately we are not able to
identify the number of aspirates that were used in each
examination.
Conclusions
In hospital routine and in the subgroup of patients eligible
for surgical resection EBUS-TBNA has been proven to be
a good tool for the primary diagnosis of lung cancer. The
negative predictive value of 89 % for mediastinal staging
of lung cancer is comparable to that reported in previous
studies, but the relatively high number of false negative
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cases points to the need for standardization of routine
strategies before, during and after EBUS.
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